Bondestam Jonas, Mäyränpää Mervi K, Ikegawa Shiro, Marttinen Eino, Kröger Heikki, Mäkitie Outi
Department of Pediatrics, Hospital for Children and Adolescents, P.O. Box 281, 00029 Helsinki, Finland.
Clin Rheumatol. 2007 Oct;26(10):1773-7. doi: 10.1007/s10067-006-0511-z. Epub 2007 Jan 6.
Progressive diaphyseal dysplasia (MIM 131300), also known as Camurati-Engelmann disease (CED), is a rare autosomal dominant craniotubular dysplasia caused by mutations in the transforming growth factor beta1 (TGF-beta1) gene. Radiographs of the long bones of a 9-year-old boy presenting with waddling gait, muscular weakness, underweight, and severe skeletal pain showed symmetric diaphyseal cortical thickening pathognomonic for CED. The diagnosis was verified by detecting a mutation in exon 4 of the TGF-beta1 gene. Full body bone mineral densitometry studies performed before treatment with prednisolone were indicative for osteoporosis (Z-scores for the lumbar spine and femoral neck -2.3 and -3.2, respectively). A transiliac bone biopsy showed markedly reduced trabecular bone volume. Oral prednisolone was initiated, and subsequently, pamidronate infusions were commenced in an attempt to prevent progression of osteoporosis. To our knowledge, this is the first time bone biopsy and bone mineral densitometry studies have been performed and bisphosphonate treatment evaluated in a child with CED.
进行性骨干发育异常(MIM 131300),也称为卡穆拉蒂 - 恩格尔曼病(CED),是一种由转化生长因子β1(TGF-β1)基因突变引起的罕见常染色体显性颅骨干发育异常。一名9岁男孩出现蹒跚步态、肌肉无力、体重不足和严重骨骼疼痛,其长骨X线片显示出CED特有的对称性骨干皮质增厚。通过检测TGF-β1基因第4外显子的突变证实了诊断。在使用泼尼松龙治疗前进行的全身骨密度测量研究表明存在骨质疏松症(腰椎和股骨颈的Z值分别为-2.3和-3.2)。经髂骨活检显示小梁骨体积明显减少。开始口服泼尼松龙,随后开始静脉输注帕米膦酸盐,试图预防骨质疏松症的进展。据我们所知,这是首次对一名CED患儿进行骨活检和骨密度测量研究,并评估双膦酸盐治疗。